Publications by authors named "D Sappey Marinier"
Article Synopsis
- The study aimed to compare the overall quality of life and treatment-related symptoms in patients with high-risk melanoma receiving either ipilimumab (ipi3 or ipi10) or high-dose interferon (HDI) after surgery.
- Results showed that patients on ipilimumab reported better health-related quality of life and fewer physical and cognitive/emotional concerns compared to those on HDI, although they experienced worse gastrointestinal symptoms.
- The findings suggest that ipilimumab (especially the lower dose, ipi3) has less toxicity and fewer treatment-specific concerns, indicating a need for managing GI issues and fatigue in these patients.
Introduction: Increased immune checkpoint inhibitor (ICI) use in various advanced cancer types has led to a parallel rise in immune-related adverse events (irAEs). Despite widespread use, ICI data in older patients remains limited. We investigate irAE prevalence in older patients receiving ICI and whether irAEs and survival are associated.
View Article and Find Full Text PDFBackground/aim: The role of cytoreductive nephrectomy (CN) for metastatic renal cell cancer (mRCC) is not clearly understood after the approval of targeted therapies, particularly in the elderly population. The aim of this study was to compare survivals between patients who did and did not receive CN.
Patients And Methods: The SEER-18 database was utilized in order to identify elderly patients with mRCC to compare overall survival (OS) and cancer-specific survival (CSS) between patients who did or did not receive CN between February 2006 and 2012.